Compare · ARVN vs KYMR
ARVN vs KYMR
Side-by-side comparison of Arvinas Inc. (ARVN) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ARVN focuses on Biotechnology: Pharmaceutical Preparations, while KYMR focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- KYMR is the larger of the two at $9.84B, about 23.3x ARVN ($423.0M).
- ARVN has been more active in the news (9 items in the past 4 weeks vs 2 for KYMR).
- Both have 25 recent analyst ratings on file.
- Company
- Arvinas Inc.
- Kymera Therapeutics Inc.
- Price
- -
- -
- Market cap
- $423.0M
- $9.84B
- 1M return
- -
- +3.84%
- 1Y return
- -
- +75.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 25
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest ARVN
- GeneDx Announces Leadership Transition
- SEC Form EFFECT filed by Arvinas Inc.
- Arvinas to Present at Jefferies Global Healthcare Conference
- VP, Chief Accounting Officer Loomis David K sold $1,475 worth of shares (232 units at $6.36), decreasing direct ownership by 0.58% to 39,961 units (SEC Form 4) (withholding tax)
- Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
- SEC Form S-3 filed by Arvinas Inc.
- SEC Form 10-Q filed by Arvinas Inc.
- Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Latest KYMR
- Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form 10-Q filed by Kymera Therapeutics Inc.
- SEC Form 8-K filed by Kymera Therapeutics Inc.
- Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
- Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
- Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
- Raymond James initiated coverage on Kymera Therapeutics with a new price target
- Chief Executive Officer Mainolfi Nello exercised 30,000 shares at a strike of $2.08 and sold $3,413,917 worth of shares (30,000 units at $113.80) as part of a pre-agreed trading plan (SEC Form 4)
- Kymera Therapeutics upgraded by Wolfe Research with a new price target